文献速递主动脉疾病

胸腹主动脉瘤开窗分支腔内修复术后救治失败预测因素

Predictors of failure to rescue after fenestrated-branched endovascular aortic repair of thoracoabdominal aortic aneurysms.
PubMed 文献 · J Vasc Surg · 2025-03-05

该研究分析27个中心2005至2022年3634例胸腹主动脉瘤开窗分支腔内修复术患者,院内死亡率为5%,主要不良事件和救治失败中位发生率分别为27%和15%。低年volume中心主要不良事件发生率更高,但中心年volume与救治失败无关,症状性/破裂性胸腹主动脉瘤是救治失败的独立预测因素。

要点

  • 胸腹主动脉瘤开窗分支腔内修复术院内死亡率为5%,救治失败中位发生率为15%。
  • 年volume低于中位数11例的中心主要不良事件发生率更高(33% vs 20%,P < .001)。
  • 症状性/破裂性胸腹主动脉瘤是救治失败的独立预测因素(OR 2.99,95%CI 1.62-5.52,P < .001)。

核心结论

  • 开窗分支腔内修复术治疗胸腹主动脉瘤的院内死亡率低,低年volume中心主要不良事件发生率更高但中心年volume与救治失败无关,症状性/破裂性胸腹主动脉瘤是救治失败的独立预测因素。

研究设计与样本

  • 国际多中心主动脉研究组27个中心2005至2022年连续纳入的3634例胸腹主动脉瘤开窗分支腔内修复术患者,数据来自美国主动脉研究联盟前瞻性医师发起器械豁免研究(10个中心)及欧洲和新西兰的回顾性中心数据。

主要发现

  • 总体技术成功率为94%,院内死亡率为5%。
  • 主要不良事件中位发生率为27%(四分位距18%-33%),救治失败中位发生率为15%(四分位距6%-21%)。
  • 年volume低于中位数(11例)的中心主要不良事件发生率显著高于年volume高于中位数的中心(33% vs 20%,P < .001)。
  • 主要不良事件的独立预测因素包括年龄(OR 1.01,95%CI 1.00-1.02,P = .02)、慢性肾脏病(OR 1.88,95%CI 1.54-2.29,P ≤ .001)、ASA分级≥3级(OR 1.70,95%CI 1.21-2.38,P = .002)、既往主动脉修复史(OR 0.74,95%CI 0.60-0.91,P = .004)、症状性/破裂性(OR 1.76,95%CI 1.36-2.28,P < .001)、I至III型胸腹主动脉瘤(OR 2.28,95%CI 1.75-2.97,P < .001)及年volume较低(<11例/年:OR 1.83,95%CI 1.40-2.38,P < .001)。
  • 症状性/破裂性胸腹主动脉瘤是救治失败的独立预测因素(OR 2.99,95%CI 1.62-5.52,P < .001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Failure to rescue (FTR), defined as mortality due to failure in responding to in-hospital complications, is an important quality indicator. This study aimed to assess incidence and predictors for FTR among centers performing fenestrated-branched endovascular aortic repair (FB-EVAR) of thoracoabdominal aortic aneurysms (TAAA). METHODS: Consecutive patients treated by FB-EVAR for TAAAs between 2005 and 2022 in 27 centers of the International Multicenter Aortic Research Group were analyzed. Data were obtained from the United States Aortic Research Consortium, which contains prospectively collected data of physician-sponsored investigational device exemption studies from 10 centers, and retrospective center data from Europe and New Zealand. FTR was defined as in-hospital mortality following ≥1 major adverse event (MAE). Primary endpoints were rates of postoperative MAEs, including major cardiac (myocardial infarction, cardiovascular collapse, acute congestive heart failure) and respiratory events, major stroke, paraplegia, acute kidney injury (AKI), and bowel ischemia requiring surgical resection or escalation of care and FTR. Multivariate analysis was performed to identify predictors for MAEs and FTR. RESULTS: There were 3634 patients (68% males; mean age, 71 ± 9 years) treated by FB-EVAR for TAAAs. Technical success was achieved in 94%, with 5% in-hospital mortality. Median incidences of MAEs and FTR were 27% (interquartile range, 18%-33%) and 15% (interquartile range, 6%-21%). There was a significantly (33% vs 20%; P < .001) higher rate of MAEs among centers with annual volume below the median (11 cases). Independent predictors for MAEs included age (odds ratio [OR], 1.01; 95% confidence interval [CI], 1.00-1.02; P = .02), chronic kidney disease (OR, 1.88; 95% CI, 1.54-2.29; P ≤ .001), ASA class ≥3 (OR, 1.70; 95% CI, 1.21-2.38; P = .002), previous aortic repair (OR, 0.74; 95% CI, 0.60-0.91; P = .004), symptomatic/ruptured (OR, 1.76; 95% CI, 1.36-2.28; P < .001), extent I to III TAAA (OR, 2.28; 95% CI, 1.75-2.97; P < .001), and lower annual volume (<11 cases/year: OR, 1.83; 95% CI, 1.40-2.38; P < .001). Symptomatic/ruptured TAAA was an independent predictor for FTR (OR, 2.99; 95% CI, 1.62-5.52; P < .001). CONCLUSIONS: FB-EVAR was performed with low in-hospital mortality. Lower volume centers had higher rates of MAEs, but center volume was not related to FTR. Symptomatic/ruptured TAAAs were independently predictive of FTR.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Vacirca A, Mesnard T, Huang Y, et al. Predictors of failure to rescue after fenestrated-branched endovascular aortic repair of thoracoabdominal aortic aneurysms. J Vasc Surg. 2025. PMID: 40054790. doi:10.1016/j.jvs.2025.02.032

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。